Compare GRPN & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | VTYX |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.4M | 713.6M |
| IPO Year | 2011 | 2021 |
| Metric | GRPN | VTYX |
|---|---|---|
| Price | $16.27 | $13.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $31.25 | $14.60 |
| AVG Volume (30 Days) | 980.2K | ★ 1.4M |
| Earning Date | 11-06-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $496,093,000.00 | N/A |
| Revenue This Year | $4.17 | N/A |
| Revenue Next Year | $10.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.21 | $0.78 |
| 52 Week High | $43.08 | $25.00 |
| Indicator | GRPN | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 75.47 |
| Support Level | $17.43 | $7.08 |
| Resistance Level | $17.93 | $9.30 |
| Average True Range (ATR) | 0.71 | 0.74 |
| MACD | -0.01 | 0.25 |
| Stochastic Oscillator | 15.72 | 80.63 |
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.